Besides breast cancer combination regiments, we are also able to use DcNP technology to formulate two leukemia regiments: venetoclax (Bcl-2 target) and zanubrutinib (BTK target) as a synchronized and long-acting drug-combination for the treatment of leukemia [35]. The gene discussed is BCL2; the disease is breast carcinoma.